Ketogal: A Derivative Ketorolac Molecule with Minor Ulcerogenic and Renal Toxicity by Russo, Roberto et al.
fphar-08-00757 November 6, 2017 Time: 18:37 # 1
ORIGINAL RESEARCH
published: 06 November 2017
doi: 10.3389/fphar.2017.00757
Edited by:
Satish Kitambi,
Karolinska Institute (KI), Sweden
Reviewed by:
Santina Chiechio,
Università degli Studi di Catania, Italy
Carmela Parenti,
Università degli Studi di Catania, Italy
*Correspondence:
Roberto Russo
roberto.russo@unina.it
†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology
Received: 27 July 2017
Accepted: 05 October 2017
Published: 06 November 2017
Citation:
Russo R, De Caro C, Avallone B,
Magliocca S, Nieddu M, Boatto G,
Troiano R, Cuomo R, Cirillo C,
Avagliano C, Cristiano C,
La Rana G, Sarnelli G, Calignano A
and Rimoli MG (2017) Ketogal:
A Derivative Ketorolac Molecule with
Minor Ulcerogenic and Renal Toxicity.
Front. Pharmacol. 8:757.
doi: 10.3389/fphar.2017.00757
Ketogal: A Derivative Ketorolac
Molecule with Minor Ulcerogenic
and Renal Toxicity
Roberto Russo1*†, Carmen De Caro1,2†, Bice Avallone3, Salvatore Magliocca1,
Maria Nieddu4, Gianpiero Boatto4, Roberta Troiano3, Rosario Cuomo5, Carla Cirillo6,
Carmen Avagliano1, Claudia Cristiano1, Giovanna La Rana1, Giovanni Sarnelli5,
Antonio Calignano1 and Maria G. Rimoli1
1 Department of Pharmacy, University of Naples Federico II, Naples, Italy, 2 Science of Health Department, School of
Medicine, Magna Graecia University, Catanzaro, Italy, 3 Department of Biology, University of Naples Federico II, Naples, Italy,
4 Department of Chemistry and Pharmacy, University of Sassari, Sassari, Italy, 5 Department of Clinical Medicine and Surgery,
University of Naples Federico II, Naples, Italy, 6 Laboratory for Enteric Neuroscience, KU Leuven, Leuven, Belgium
Ketorolac is a powerful non-steroidal anti-inflammatory drug (NSAID), with a great
analgesic activity, present on the Italian market since 1991. Despite the excellent
therapeutic activity, the chronic use of ketorolac has long been limited owing to the
high incidence of gastrointestinal and kidney side events. In our previous study, we
demonstrated that ketorolac–galactose conjugate (ketogal), synthesized and tested
in a single-dose study, was able to reduce ulcerogenicity, while preserving the high
pharmacological efficacy of its parent drug. In this paper, in order to verify the
suitability of this compound, for repeated administration, ex vivo experiments on naïve
mice were performed. Mice were treated for 5 or 7 days with the highest doses
of two drugs (ketorolac 10 mg/kg and ketogal 16.3 mg/kg), and the expression of
both gastric COX-1 and PGsyn was evaluated. Results showed that oral ketorolac
treatment significantly reduced both enzymes; surprisingly, oral treatment with ketogal
did not produce significant variation in the expression of the two constitutive enzymes.
Moreover, histological experiments on stomach and kidneys clearly indicated that
repeated administration of ketogal induced lower toxicity than ketorolac. At same
time, in vivo results clearly showed that both ketorolac and ketogal had a similar
therapeutic activity in a model of inflammation and in pain perception. These effects
were accompanied by the reduction of enzyme expression such as COX-2 and iNOS,
and by the modulation of levels of nuclear NF-κB and cytosolic IκB-α in the inflamed
paws. These very encouraging results demonstrate for the first time that ketogal could
represent a valid and novel therapeutic alternative to the ketorolac and might pave the
way for clinical studies.
Keywords: ketorolac, ketogal, analgesia, gastrointestinal toxicity, histological evaluation, PAS staining
Abbreviations: ACN, acetonitrile; [bmim][PF6], 1-butyl-3-methylimidazolium hexafluorophosphate; CMC,
carboxymethyl cellulose; COX, cyclooxygenase; DIPG, 1,2,3,4-di-O-isopropylidene-D-α-galactopyranose; DMAP,
4-(dimethylamino)pyridine; EDC, N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide hydrochloride; GAA, glacial
acetic acid; GFR, glomerular filtration rate; GI, gastrointestinal; i.p., intraperitoneal; MRT, mean residence time; NSAIDs,
non-steroidal anti-inflammatory drugs; PAS, periodic acid–Schiff; PBS, phosphate buffered saline; PFA paraformaldehyde;
PGs, prostaglandins; PGsyn, prostaglandin synthetase; PT, Plantar Test; PWT, Paw withdrawal threshold; RPM, revolutions
per minute; TFA, trifluoroacetic acid.
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INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) are the
therapeutic agents of first choice for the treatment of
inflammation, pain, and fever. The term NSAID refers to a
group of structurally diverse chemical compounds that share
the ability to inhibit the activity of the prostaglandin (PG)
biosynthetic enzymes, the cyclooxygenase (COX) isoforms 1
and 2. It is shown that anti-inflammatory activity of NSAIDs is
also due to degradation of IκB-α and nuclear translocation of
NF-κB both in vitro and in vivo (Stark et al., 2001; Loveridge
et al., 2008). Moreover, NF-κB stimulates the expression of
enzymes whose products contribute to the pathogenesis of
the inflammatory process, including the inducible form of
nitric oxide synthase (iNOS) and the COX-2 (Pahl, 1999).
Unfortunately, gastrointestinal (GI) toxicity still remains the
biggest problem for current NSAIDs-based therapies. The
number of new developed drugs approved annually continues
to decline because of the problems related to pharmacological
safety. It is the case of the selective COX-2 inhibitors that in
the beginning were very promising because of their selective
inhibitor effect, which reduced GI side effects. However, very
soon the adverse cardiovascular effects have dramatically
reduced their use in the clinical practice (Drazen, 2005;
McGettigan and Henry, 2006). GI side effects produced by
non-selective COX-1/-2 inhibitors are either due to direct
contact or indirect effect of the drug on the gastrointestinal
mucus membrane. Acidic nature of NSAIDs, ion trapping,
and inhibition of cytoprotective prostaglandins are some
of the reasons for the GI adverse effects (Cioli et al., 1979;
Rainsford, 1989). Recently, a great attention has been paid
to the derivatization of NSAIDs carboxyl group in order to
develop gastro sparing prodrugs. Among the NSAIDs on the
market, ketorolac appears a good candidate. This non-steroidal
and non-narcotic drug is administered systemically (via oral
and parenteral route) for the control of mild-to-moderate
pain as well as of some postoperative and cancer pain, and its
mechanisms are well known (O’Hara et al., 1987; Brown et al.,
1990; Joishy and Walsh, 1998; Mercadante and Giarratano,
2013). Despite its high therapeutic potential, clinical use has
been strongly limited because of the toxicity. In fact, long-term
exposure to this drug has been correlated with an enhanced
risk of gastrointestinal bleeding and renal failure (Litvak and
McEvoy, 1990; Laporte et al., 2004; Boyer et al., 2010). For
this reason, its safety profile has been carefully monitored
during the last years and its use limited to the short-term
treatments (Gillis and Brogden, 1997; Dula et al., 2000). Several
evidences have shown that restricting the dosage and duration
of exposure, as well as use in patients younger than 65 years
old significantly reduces adverse effects, but this therapeutic
approach is not always effective (Soleyman-Zomalan et al.,
2017). Many efforts have been made to synthesize new prodrugs
form ketorolac, by masking its carboxylic acid group (Suthar
and Sharma, 2015), obtaining a minor gastrointestinal toxicity
by contact. Moreover, to obtain a reduction in GI toxicity, it is
important the role of endogenous enzymes, such as prostaglandin
synthetase (PGsyn), and COX-1 (Miller and Jacobson, 1979;
Brzozowski et al., 2005; Szabo, 2014). The observation that
non-selective COX-1/-2 inhibitors block the activity of the
PGsyn system both in vitro and in vivo suggests that GI toxicity
encountered in humans treated with NSAIDs may be due to
a reduction of COX-1 activity and deficiency of endogenous
PGs (Miller and Jacobson, 1979). Moreover, the literature data
also underline that altered expression of these two constitutive
enzymes is necessary for maintenance of tissue homeostasis.
In particular, recently, Mard et al. (2016) showed that the
level of protein expression of COX-1 in indomethacin-treated
animals was significantly lower than in normal untreated
animals.
Based on these evidences, the aim of this paper was to
evaluate gastric toxicity (by COX-1 and PGsyn expression and
by histological study) and renal alteration (by metabolic cages
and histological study) after repeated ketorolac and ketogal
oral treatment in naïve mice. Moreover, therapeutic activity in
acute (carrageenan) and chronic (incision paw) pain models
was tested and pro-inflammatory enzyme expression (iNOS
and COX-2) and mediators (NF-κB and IκB-α) were also
evaluated.
MATERIALS AND METHODS
Drugs and Chemicals
Ketorolac was purchased from commercial sources (Sigma–
Aldrich, Milan, Italy) as free acid. Ketogal was synthesized
as described (Magliocca et al., 2017). The synthesis was
carried out with green strategies and involves two steps. First,
esterification of ketorolac with 1,2,3,4-di-O-isopropylidene-D-
α-galactopyranose (DIPG) in the presence of N-ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) as a
condensing agent and 4-(dimethylamino) pyridine (DMAP),
as catalyst in [bmim][PF6], then, ketals were completely
removed in a mixture of ACN, hydrochloric acid 1N, and
GAA at reflux for 40 min. Evaporation of the solvent
gave a residue which was purified on a chromatography
column with silica gel by using ethyl acetate as eluent so
as to obtain ketogal. Indomethacin was obtained by Sigma–
Aldrich, (Milan, Italy), and it was used only for histological
experiments.
Animals
The 10-week-old male Swiss CD1 mice (30–35 g) were purchased
from Charles Rivers (Calco, Italy). They were housed in cages
in a room kept at 22 ± 1◦C on a 12 h:12 h light/dark
cycle. All animals were acclimated to their environment for
1 week and had ad libitum access to water and standard
rodent chow diet. All procedures involving mice were carried
out in accordance with the Institutional Guidelines and
complied with the Italian Ministry of Health and associated
guidelines from European Communities Council Directive. The
procedures reported here were approved by the Institutional
Committee on the Ethics of Animal Experiments (CSV) of
the University of Naples “Federico II” and by the Ministry
of Health under protocol no. 2014-0084607. At the end
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of all experiments, the animals were euthanized by CO2
overdose.
IN VIVO EXPERIMENT
Anti-inflammatory Activity
Paw edema was induced by a subplantar injection of λ–
carrageenan (1%) into the right hind paw (D’Agostino
et al., 2007). Vehicle, Ketorolac, and ketogal were orally
administrated for 5 days. Paw volumes were measured by
a plethysmometer apparatus (Ugo Basile, Italy) at different
time intervals before injection (0) and 1, 2, 3, 6, and
24 h after administration of carrageenan. The increase of
paw volume was evaluated as the difference between the
paw volume measured at each time point and the basal
paw volume measured immediately before carrageenan
injection.
Plantar Incision
Postoperative pain was induced by incision paw according to the
method described by Pogatzki and Raja (2003). All mice were
anesthetized with enflurane/O2 mixture and were maintained
by a mask during the administration procedure. The left paw
was disinfected with Betadine; a 0.5-cm longitudinal incision
was made with a blade, through skin and fascia of the plantar
aspect of the foot, starting 0.3 cm from the proximal edge of
the heel and extending toward the toes. The underlying muscle
was elevated with a curved forceps, leaving the muscle origin
and insertion intact. The skin was closed with a single 8–0
nylon suture. The incisions were checked daily and any signs
of wound infection or dehiscence excluded the animal from the
study.
Mechanical Hyperalgesia
Latencies of paw withdrawal (g) were evaluated by mechanical
stimuli using the Randall–Selitto analgesiometer for mice (Ugo
Basile, Italy, model 37216). Vehicle, Ketorolac, and Ketogal were
orally administrated for 5 days; in carrageenan experiment,
hyperalgesia was assessed on ipsilateral paw before (0) and 1, 2,
3, 6, and 24 h; while in postoperative study, mechanical pain was
performed at day 5 following incision. Each paw was tested twice
per session. Cutoff force was set at 100 g to avoid tissue injury to
the animals.
Thermal Hyperalgesia
Thermal hyperalgesia was examined by measuring the latency to
withdrawal of the hind paws from a focused beam of radiant heat
applied to the plantar surface using a Plantar Test apparatus (Ugo
Basile, Milan, Italy). The days before experiment, animals were
placed in a transparent Perspex box with a thin glass floor and
allowed to acclimatize for 30 min. Ketorolac and ketogal were
orally administrated for 5 days; withdrawal latencies to radiant
heat were measured on inflamed paw at day 5 at different time
intervals (1, 2, 3, 6, and 24 h). Cutoff was set at 30 s to avoid tissue
injury to the animals.
FIGURE 1 | Evaluation of ulcerogenic activity of repeated (for 5 or 7 days)
treatment of ketorolac (10 mg/kg/os, white–gray columns), ketogal
(16.3 mg/kg/os, black–gray columns), and ctr (vehicle, os, white columns).
Individual score from 0 to 3 was assigned; the sum of total scores was used
for comparison. Data are shown as mean ± SEM of six animals per group.
The significance of differences between groups was determined by one-way
ANOVA followed by post hoc Bonferroni’s test. ∗P < 0.05 vs. ctr day 5;
##P < 0.01 vs. ctr day 7; §P < 0.05 vs. ketorolac day 7.
Volume of Urine
Fasting mice (12–14 h) were treated for 5 or 7 days with ketorolac
(10 mg/kg/os), ketogal (16.6 mg/kg/os) or vehicle; 1 h following
oral administration, mice were placed in metabolic cages for 24 h
and the volume of urine was measured (n = 6). Results are
expressed as the total amount of urine (mL) of 5 or 7 days.
EX VIVO EXPERIMENT
Protein Extraction and Western Blot
Analysis
To obtain cytosolic protein extracts, skin was removed
and paws were homogenized in extraction buffer [0.32 M
sucrose, 10 mM TRIS–HCl pH 7.4, 1 mM ethylene glycol-
bis(β-aminoethyl ether)-N,N,N′,N′–tetraacetic acid (EGTA),
2 mM ethylenediaminetetraacetic acid (EDTA), 5 mM
NaN3, 10 mM 2-mercaptoethanol, 50 mM NaF, 0.2 mM
phenylmethylsulphonylfluoride (PMSF), 0,15 µM pepstatin
A, 20 µM leupeptin, and 1 mM sodium orthovanadate]. The
homogenates were chilled on ice for 15 min and then centrifuged
at 1000 g for 10 min at 4◦C; and the supernatant was stored
at −80◦C until use. To obtain cytosolic fraction, pellets were
suspended in the supplied complete lysis buffer containing 1%
Triton X-100, 150 mM NaCl, 10 mM Tris–HCl pH 7.4, 1 mM
EGTA, 1 mM EDTA, 0,2 mM PMSF, 20 µM, 0,2 mM sodium
orthovanadate and then centrifuged for 30 min at 15000 g
at 4◦C.
Frozen stomachs were rapidly homogenized in ice-cold
hypotonic lysis buffer (10 mM HEPES, 1.5 mM MgCl2, 10 mM
KCl, 0.5 mM PMSF, 1.5 µg/ml soybean trypsin inhibitor, 7 µg/ml
pepstatin A, 5 µg/ml leupeptin, 0.1 mM benzamidine, 0.5 mM
dithiothreitol) and incubated in ice for 45 min. The cytoplasmatic
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FIGURE 2 | Modulation of COX-1 (A) and PGE synthase (B) expression in stomach of naïve mice at 5 and 7 days following oral ketorolac (10 mg/kg, white–gray
columns), ketogal (16.3 mg/kg, black–gray columns), and ctr (vehicle, white columns) administration. Data are shown as mean ± SEM of 6 per group. The
significance of differences between groups was determined by one-way ANOVA followed by post hoc Bonferroni’s test. ∗P < 0.05 vs. ctr day 5; ◦P < 0.05 vs.
ketorolac day 5; §P < 0.05 vs. ketorolac day 7.
fraction was then obtained by centrifugation at 13,000 g for
15 min at 4◦C.
Protein concentrations were estimated by the Bio-Rad protein
assay using bovine serum albumin as standard. Paw (70 µg)
and stomach (30 µg) lysate proteins were dissolved in Laemmli
sample buffer, boiled for 5 min and separated on acrylamide
gel electrophoresis and transferred to nitrocellulose membrane
(240 mA for 40 min at room temperature). The filter was then
blocked with 1X phosphate buffer saline (PBS) and 3% non-fat
dried milk for 45 min at room temperature and probed with
anti-cyclooxygenase (COX)-2 (dilution 1:1000; BD Bioscience,
from Becton Dickinson, Buccinasco, Italy), anti-inducible nitric
oxide synthase (iNOS) antibody (dilution 1:1000; BD Bioscience),
anti-NF-κB p65 (dilution 1:500; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, United States), or anti-IκB-α (dilution 1:500;
Santa Cruz Biotechnology, Inc.) antibody for cytosolic and
nuclear paw lysates. Stomach lysates were probed with anti-
COX-1 (dilution 1:1000; Santa Cruz Biotechnology, Inc.) and
anti-prostaglandin E (PGE)-synthase (dilution 1:1000; Santa
Cruz Biotechnology, Inc.) antibody. The secondary antibody was
incubated for 1 h at room temperature. The immune complex
visualized by Image Quant (GE Healthcare, Milan, Italy). The
protein bands were densitometrically analyzed with a model GS-
700 imaging densitometer (Bio-Rad Laboratories, Milan, Italy).
To ascertain that blots were loaded with equal amounts of
protein lysates, they were also incubated in the presence of
the antibody against the β-actin protein (clone AC-15; dilution
1:15000, Sigma–Aldrich).
Ulcerogenicity Studies
Non-steroidal anti-inflammatory drugs (NSAIDs)-induced
gastric damage in mice is evaluated following the procedure
described by Chan et al., 1995. In fasted (16–18 h) mice (n= 6 for
each group), ketorolac free acid (10 mg/kg), ketogal (16.3 mg/kg),
or vehicle (CMC 0.5%) were administered orally for 5 days; at last
day, mice were euthanized 1 h after treatment and the stomach
was excised along its greater curvature, rinsed with normal
saline, and the mucosa was examined by means of a magnifying
glass for the presence of irritation or frank hemorrhagic lesions
(ulcers). Irritation/ulcers were assigned a score from 0 to 3;
0= no irritation, 3= high irritation. The sum of total scores was
used for comparison.
Histological Evaluation
In another set of experiments, we evaluated histological aspect
of stomach and kidneys from fasting mice (n = 6 for each
group; 12–14 h) treated for 5 days with ketorolac (10 mg/kg/os),
ketogal (16.3 mg/kg/os), indomethacin (15 mg/kg/os), and
vehicle (CMC 0.5%), and from untreated fed mice. Mice
were deeply anesthetized with pentobarbitone (50 mg/kg−1,
IP) and transcardially perfused with PBS followed by 4%
paraformaldehyde (PFA). Then, the stomachs and kidneys were
excised and fixed in 10% buffered paraformaldehyde solution
at 4◦C for 24 h. Finally, the samples were processed for wax
embedding according to routine protocols, serial sections were
cut and stained with hematoxylin–eosin. Periodic acid–Schiff
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FIGURE 3 | Histological observations of different treatments on the stomach
of mouse, PAS staining. (A,B) White stomach, the gastric mucosa shows
regular morphology with normal complement of mucosal lineage. (C,D)
Vehicle-treated mice stomach presents normal histological appearance. Slight
alterations are rarely observed. (E,F) Indomethacin-treated stomach has
severe lesions of mucosa, with foveolar and parietal cells eroded (frame).
Prominent inflammatory infiltrate (∗) and oedema (arrow) are evident. (G,H)
Ketorolac-treated stomach shows necrotic area (frame) with a severe infiltrate
(∗) and oedema (arrow). (I,J) Ketogal-treated stomach that shows the gastric
mucosa has a slight alteration and normal mucus production.
(PAS) was used to highlight mucin, glycogen, and glycoproteins.
Sections were oxidized in 0.5% periodic acid solution for 10 min,
rinsed in double-distilled water, and stained with Schiff ’s reagent
in the dark for 45 min. The reaction was blocked by repeated
washing in 2.5% sodium bisulphite in 0.05 N HCl (Avallone et al.,
2015).
Statistical Analysis
Statistical analyses were performed on raw data using Prism 5
Graphpad software (GraphPad Software Inc., San Diego, CA,
United States). In vitro data are presented as mean ± SEM,
FIGURE 4 | Effect of 5 or 7 days of oral ketorolac (10 mg/kg, white–gray
columns), ketogal (16.3 mg/kg, black–gray columns), and ctr (vehicle, white
columns) administration on total urine volume in naïve mice. Data are shown
as mean ± SEM of six animals per group. The significance of differences
between groups was determined by one-way ANOVA followed by post hoc
Bonferroni’s test. ∗P < 0.05 vs. ctr day 5; ##P < 0.01 vs. ctr day 7; §P < 0.05
vs. ketorolac day 7.
results was expressed as optical density (OD) (arbitrary units;
mm2) and normalized against the expression of the housekeeping
protein β-actin. The significance of differences between groups
was determined by one-way repeated measurements ANOVA
followed by post hoc Bonferroni’s in vivo data are presented
as mean ± SEM; pain tests were expressed as paw withdrawal
threshold (PWT) expressed in gram (g) for mechanical
hyperalgesia and in second (s) for thermal hyperalgesia. The
significance of differences between groups was determined by
one- or two-way repeated measurements ANOVA followed by
post hoc Bonferroni’s test. P < 0.05 was considered statistically
significant for all tests.
RESULTS
Evaluation of Gastric Toxicity after
Repeated Oral Administration of
Ketorolac or Ketogal
Non-steroidal anti-inflammatory drug (NSAID) long-
term administration induces significant stomach ulcers
and histopathological changes in kidney, with consequent
nephrotoxicity (Gooch et al., 2007). Our data confirm these
hypothesis, since we showed that 5 or 7 days of oral ketorolac
(10 mg/kg/os, gray–white columns) treatment provoked a
considerable number of ulcers in stomach, compared to control
group (gray–white columns) (Figure 1; ∗P < 0.05 vs. ctr day 5,
and ##P < 0.01 vs. ctr day 7). By contrast, equimolecular oral
dose of ketogal (16.6 mg/kg/os, gray–black columns) did not
induce an increase of numbers of ulcers compared to vehicle-
treated mice, but it is noteworthy lower if compared to ketorolac
(Figure 1). Moreover, ketogal-treated mice showed following 7
treatment days, a lower ulcers formation if compared to ketorolac
(Figure 1; §P < 0.05 vs. ketorolac day 7). To confirm of these
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FIGURE 5 | Histological observations of different treatments on the kidney of
mouse, hematoxylin-eosin (A–E) – PAS staining (A′–E′). (A,A′) White and
(B,B′) vehicle-treated mice kidney, they show the typical organization in
nephrons. (C,C′) Indomethacin-treated kidney highlights contracted glomeruli,
a slight cytoplasmic vacuolization of the tubular epithelium and a higher PAS
positivity. (D,D′) Ketorolac-treated kidney shows many contracted glomeruli,
marked cytoplasmic vacuolization and a strong PAS positivity of the tubular
epithelium. (E,E′) Ketogal-treated kidney exhibits a normal morphology of the
nephron such as the positivity of the neutral mucopolysaccharides.
data, we evaluated COX-1 and PGsyn expression in the stomach
of naïve mice trough WB analysis (Figure 2); results showed
that COX-1 (Figure 2A) and PGEsyn (Figure 2B) expression
was significantly reduced in ketorolac-treated mice following
5 and 7 days (Figures 2A,B, gray–white columns; ∗P < 0.05
vs. ctr), while oral equimolecular dose of ketogal surprisingly
did not produce significant variation of these two constitutive
enzymes. Significant difference was observed between ketorolac
group and ketogal-treated mice, to confirm that our prodrug
has a better toxicological profile (Figure 2; ◦P < 0.05 vs.
ketorolac day 5 and §P < 0.05 vs. ketorolac day 7). These data
were also supported by histological analysis. Light microscopy
observations on the stomach, after PAS staining, showed that in
untreated mice the gastric mucosa had a normal complement
of mucosal lineage: chief cells that produce pepsinogen, parietal
cells in the intermediate zone, hydrogen chloride secreting,
and foveolar mucus-producing cells (Figures 3A,B). Also
vehicle-treated mice had a regular morphology with normal
mucus production and a lack of inflammatory infiltrate; slight
alterations are rarely observed (Figures 3C,D). The stomach
treated with indomethacin (15 mg/kg/os), used as positive
control, exhibits severe lesions of mucosa, mainly at the level
of foveolar and parietal cells that are eroded (ulcers) with
an inflammatory infiltrate in the lower part of mucosa and
sub-mucosa (Figures 3E,F). Stomach treated with ketorolac
(10 mg/kg/os for 5 days) presented necrotic areas with the
complete loss of the three cell types and an evident inflammatory
infiltrate; ulcer areas with an initial disintegration of the mucosal
surface, particularly at the level of cells foveolar, were evident
as well (Figures 3G,H). Finally, gastric mucosa of mice treated
with ketogal (16.3 mg/kg/os for 5 days) showed a considerable
improvement in the response to the drug with slight alterations
and normal mucus production (Figures 3I,J).
Evaluation of Kidney Toxicity after
Repeated Oral Administration of
Ketorolac or Ketogal
Non-steroidal anti-inflammatory drugs (NSAIDs) alter renal
function through their effects on renal PGs, and these become
critically involved in the control of renal hemodynamics and
in maintaining the glomerular filtration rate (GFR) (Radi,
2012). We evaluated the total volume of urine in mice treated
with ketorolac (10 mg/kg/os) or ketogal (16.3 mg/kg/os) and
we found that oral repeated ketorolac treatment significantly
reduced the total urine volume at 5 and 7 days (Figure 4,
gray–white columns, ∗P < 0.05 vs. ctr day 5 and ##P < 0.01
vs. ctr day 7), while oral ketogal treatment did not produce
any significant effect on urine volume compared to control
group (Figure 4, black–white columns). Ketogal-treated mice
showed following 7 treatment days, a more high volume of
urine if compared to ketorolac (Figure 4; §P < 0.05 vs.
ketorolac day 7), data that underline a best safety profile
respect its parent drug. To confirm these data, histological
studies were performed. Hematoxylin-eosin and PAS staining
were used to highlight different kind of damage (Figure 5).
Our study focused on the glomerular morphology and the
evaluation of neutral mucopolysaccharides. Light microscopy
observations showed that in the untreated and vehicle-
treated mice, the kidney maintains the typical organization
in nephrons, each one composed of the glomerulus, proximal
tubule, descending and ascending loops of Henle, straight
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FIGURE 6 | Effect of 5 days of oral ketorolac (10 mg/kg), ketogal (16.3 mg/kg), and ctr (vehicle) administration in paw oedema (A), mechanical (B), and thermal (C)
hyperalgesia by carrageenan. Pharmacological activity was evaluated at 1–2–3–6–24 h following drugs administration; basal represent values before carrageenan
injection. Data are shown as mean ± SEM of six animals per group. The significance of differences between groups was determined by two-way ANOVA followed by
post hoc Bonferroni’s test. ∗P < 0.05, ∗∗P < 0.01 vs. ctr.
FIGURE 7 | Evaluation of IkB-α degradation (A), the translocation of the p65 subunit of NF-kB into the nucleus (B), COX-2 (C), and iNOS (D) enzymes expression in
the carrageenan-induced paw oedema at 5 and 7 days following oral ketorolac (10 mg/kg, white–gray columns), ketogal (16.3 mg/kg, black–gray columns), and ctr
(vehicle, white columns) administration. Data are shown as mean ± SEM of six animals per group. The significance of differences between groups was determined
by one-way ANOVA followed by post hoc Bonferroni’s test. ∗P < 0.05 vs. ctr.
segment, macula densa, and distal tubule (Figures 5A–B′).
Kidney treated with indomethacin (15 mg/kg/os) display
contracted glomeruli detached from Bowman’s capsule, and
a slight cytoplasmic vacuolization of the tubular epithelium
(Figures 5C,C′). PAS positivity is more marked in this treatment
and the mucopolysaccharides seem to fill completely the tubular
lumen which appears already reduced (Figure 5C′). Kidney
treated with ketorolac (10 mg/kg/os for 5 days) showed a loss
of consistency and a more marked cytoplasmic vacuolization
of the tubular epithelium. Many glomeruli are contracted
and there is an increase in PAS positivity of some tubules
(Figures 5D,D′). Lastly kidney treated with ketogal exhibits a
remarkable restoration of the normal morphology of the nephron
(Figures 5E,E′), even though some contracted corpuscles are
still present. The neutral mucopolysaccharides appear normal
(Figure 5E′).
Anti-inflammatory and Anti-hyperalgesic
Effects of Repeated Oral Ketorolac or
Ketogal Administration
We also evaluated therapeutic properties of two drugs following
repeated administration. Intraplantar injection of carrageenan
induced both paw edema and hyperalgesia (Figure 6A, black
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circle; Figures 6B,C, black column), as expected, repeated oral
administration for 5 days with ketorolac (10 mg/kg) reduced paw
edema (Figure 6A) and mechanical (Figure 6B) and thermal
(Figure 6C) hyperalgesia at all experimental points (1, 2, 3, 6,
and 24 h). Equimolecular doses of ketogal (16.3 mg/kg) showed
similar anti-inflammatory and analgesic activities. Similar results
were obtained also after 7 days of treatment (data not shown).
In order to investigate the mechanism by which ketorolac and
ketogal attenuate the inflammatory pathway involved in both
edema and pain perception, we analyzed cytosolic COX-2 and
iNOS expression and IκB-α and nuclear NF-κB p65 extracts
of inflamed paws. On days 5 and 7, ketorolac and ketogal
significantly prevented IκB-α degradation (Figure 7A) and the
translocation of the p65 subunit of NF-κB into the nucleus
(Figure 7B). Inflammatory enzymes and cytokines, whose
expression depends on the transcriptional NF-κB activation,
were also determined. As shown in Figures 7C,D, ketorolac
and ketogal, respectively, reduced significantly COX-2 and
iNOS expression in the inflamed paws. Finally, we tested two
drugs in postoperative pain; following incision of paw, operated
vehicle–animals showed signs of hyperalgesia if compared to
naïve mice (Figure 8; ∗P < 0.05 vs. naïve). At day 5, after
repeated oral treatment, ketorolac (10 mg/kg/os) and ketogal
(16.3 mg/kg/os) showed a significant anti-hyperalgesic effect
(Figure 8; #P < 0.05 vs. ctr). No effects were observed
on the contralateral paws (non-operated paw) (data not
shown).
DISCUSSION
In this paper, we clearly show that repeated administration
of ketorolac–galactose conjugate (ketogal) exerted a significant
therapeutic activity, similar to its parent drug ketorolac, but with
lower toxicity. In particular, our data demonstrated that using
an experimental protocol characterized by repeated ketorolac
administration for at least 5 days, treatment that is usually used in
cause of chronic inflammation or in cause of postoperative pain, a
noteworthy gastric and renal toxicity was induced. Surprisingly,
in same experimental conditions, ketogal showed a remarkable
safety profile while maintaining therapeutic activities of its parent
drug.
Gastrointestinal (GI) toxicity exerted by NSAIDs owes more
mechanisms of action and among them there is the direct
contact of carboxylic group with gastric mucosa, a phenomenon
called ion-trapping. Masking the carboxylic group with a vector
reduces the contact with mucosa and this finally decreases at
least in part the toxicity of the NSAID (Sigthorsson et al.,
2000). In our case, the esterification with galactose, not only
improves pharmacokinetic profile of ketorolac, but also increases
its therapeutic activity (Curcio et al., 2009). To the best of
our knowledge, none of the ketorolac’s prodrug reported in
previous studies has ever shown this important and unexpected
effect. In a recent review, it has been raised criticism on the
approaches and strategies employed in the last two decades
to design and develop safer NSAIDs, which mainly focused
on the amelioration of GI toxicity (Suthar and Sharma, 2015).
FIGURE 8 | Effect of 5 days of oral ketorolac (10 mg/kg, white–gray columns),
ketogal (16.3 mg/kg, black–gray columns), and ctr (vehicle, white columns)
administration in postoperative pain by paw’s incision. Naïve represent mice
without surgery. Data are shown as mean ± SEM of six animals per group.
The significance of differences between groups was determined by one-way
ANOVA followed by post hoc Bonferroni’s test. ∗P < 0.05 vs. naïve; #P < 0.0
vs. ctr.
Another important mechanism through which NSAIDs induce
toxicity, after absorption and metabolism, is due to alteration
the activities of PGs (Gambaro and Perazella, 2003; Huerta
et al., 2005). Although several factors have been postulated as
pathogenic elements of NSAID-induced GI damage, a deficiency
of PGs has clearly been shown to play a critical role in the
pathogenesis of these lesions (Whittle, 1981; Tanaka et al.,
2002; Park et al., 2006). In fact, the correlation between
NSAID and GI toxicity has been correlated with their ability
to inhibit mucosal PG synthesis (Tanaka et al., 2001). It as
well known that a long-term use of non-selective COX-1/-2
inhibitors results in gastric ulcers due to loss of physiological
COX activity and to reduction of PGs production (Miller
and Jacobson, 1979; Vane and Botting, 1995; Brzozowski
et al., 2005; Szabo, 2014). Novel findings suggest that for
maintenance of physiological functions and tissue homeostasis
not only it is important for the evaluation of COX-1 and
PGsyn activity, but also a significant role is also due to
evaluation of protein expression of these constitutive enzymes
(Mard et al., 2016). Here, for the first time we showed that
ketorolac-treated animals produced a significant reduction of
COX-1 and PGsyn expressions in naïve mice if compared to
vehicle group, probably through genetic mechanism, as others
NSAIDs reported in the literature data (Shinji et al., 2005;
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Korotkova and Jakobsson, 2011; Calvello et al., 2012; Mard
et al., 2016). It is well known that products of the COX
pathway, such as PGs, are ligands of peroxisome proliferator-
activated receptors (PPARs) (Kliewer et al., 1994; Forman
et al., 1995; Scher and Pillinger, 2009). Probably, a minor
activity of PGs induces an alteration in PPARs pathways.
Several manuscripts showed the potential activity of these
nuclear receptors in numerous pathologies, underline the
necessity to keep the activity of these receptors to preserve
the physiological integrity and wellness (Keller et al., 2000;
Ehrmann et al., 2002). Surprisingly, repeated treatment of ketogal
did not produce significant variation of expression of these
two constitutive enzymes respect to vehicle group. These data
were confirmed by histological experiments on stomach; in
fact, ketogal-treated mice showed stomach tissue less damaged,
ulcers significantly reduced, and normal mucus production,
whereas in ketorolac-treated mice, necrotic and ulcer areas
with an initial disintegration of the mucosal surface were
evident. Finally, based on these last evidences and on lessened
“topical” effect, thank to esterification of the carboxylic group
with galactose, our derivate is effectively safer than its parent
drug.
Miller and Jacobson (1979) were the first to underline the
important role of PG synthetase in the integrity of stomach,
the observation that non-selective COX-1/-2 inhibitors block
the activity of this enzyme suggest that GI toxicity by NSAIDs
may be due to a deficiency of endogenous PG. In light of
this effect, the current pharmacological therapy involves the
use of supplementation with PGE2 derivative to prevent COX-
1/-2 inhibitor-induced GI toxicity (Kunikata et al., 2001), or
use COX-2 selective inhibitors. About this approach with
selective COX-2 inhibitors, it is well known that these drugs
raise important questions about the cardiovascular toxicity. In
addition, the inhibition of both COX-1 and COX-2 was required
for NSAID-induced GI toxicity injury, suggesting a role of
COX-2 as well as COX-1 in maintaining the mucosal integrity
of these tissues (Tanaka et al., 2002; Laine et al., 2008). Therefore,
the advantage of using a non-selective COX inhibitors with low
toxicity still remains a goal of many preclinical researches. As
previously reported, ketogal is not a simple prodrug, but it could
be looked at as a new chemical entity (Melisi et al., 2011; Cardani
et al., 2014). Several manuscripts on NSAIDs prodrugs obtained
blocking the free carboxylic group of NSAIDs only argue the
gastrolesivity and neglect others crucial side effects (Szabo, 2014;
Suthar and Sharma, 2015). To the difference of these papers, in
our study we also evaluated renal toxicity. As aspect, 5 or 7 days
of ketorolac administration induced a significant kidney toxicity,
evaluated by reduction of urine volume and by histological
study. Surprisingly, ketogal administration did not produce any
significant effect on urine volume, and a better morphology of
the nephron was observed, confirming further that our prodrug
has a better safety profile than its parent drug. The other aim of
this study was to evaluate therapeutic efficacy of ketogal following
repeated treatment. Ketorolac is today used for inflammation
and for the control of mild to moderate pain as well as of some
postoperative (O’Hara et al., 1987; Brown et al., 1990; Joishy
and Walsh, 1998; Mercadante and Giarratano, 2013). Here we
reproduced animal models of these two commune pathologies by
carrageenan-induced inflammation and by incision paw-induced
postoperative pain. Our data clearly showed that prodrug was
able to reduce the inflammatory process and pain perception, as
well as ketorolac. In particular, our results showed that ketorolac
and equimolecular dose of ketogal reduced both inflammation
and pain induced by carrageenan, and that repeated treatment
was also effective in postoperative pain. These effects was
confirmed by the reduction of pro-inflammatory enzymes such
as COX-2 and iNOS, and by the modulation of expression
of nuclear NF-κB and cytosolic IκB-α. It is well known that
these factors play a key role in inflammatory process both
in vitro (Jang et al., 2017) and in vivo (Philkhana et al., 2017),
and their reduction supports our hypothesis that ketogal, such
as ketorolac, has a significant anti-inflammatory effect. These
very encouraging results demonstrate for the first time that
ketogal could be a valid and novel therapeutic alternative to
the ketorolac. In addition, a prodrug of a powerful NSAID, as
ketorolac, which preserves its pharmacological activity, can be
of great interest to decrease the number of hospitalizations and
to avoid the use of gastroprotective drugs, such as proton pump
inhibitors, themselves not devoid of toxicity (Targownik et al.,
2008; Wallace et al., 2011). In this scenario, the exploitation of
a well-known compound already on the market and coupled
with a non-toxic molecule, i.e., galactose, is undoubtedly an
effective solution in terms of economy, safety, and efficacy for
patients.
CONCLUSION
We demonstrated that ketogal is a valid substitute of its original
molecule ketorolac, due to the balance between therapeutic and
toxic effects. Though further investigations are necessary to better
characterize ketogal features, we strongly believe that it might be
successfully tested in clinical studies.
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